bioAffinity Technologies (NASDAQ:BIAF) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of bioAffinity Technologies (NASDAQ:BIAF) from a sell rating to a hold rating in a research report report published on Monday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Monday, July 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, bioAffinity Technologies currently has a consensus rating of “Sell”.

bioAffinity Technologies Stock Performance

Shares of bioAffinity Technologies stock opened at $0.49 on Monday. The company has a current ratio of 1.36, a quick ratio of 1.34 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.32 million, a PE ratio of -0.07 and a beta of -1.04. The company has a 50 day moving average of $0.90 and a 200-day moving average of $1.64. bioAffinity Technologies has a 1-year low of $0.49 and a 1-year high of $13.50.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.10) by $1.46. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 196.80%. The business had revenue of $1.51 million for the quarter, compared to analysts’ expectations of $1.70 million.

Institutional Investors Weigh In On bioAffinity Technologies

A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC bought a new stake in bioAffinity Technologies in the 4th quarter worth about $36,000. Scientech Research LLC purchased a new position in shares of bioAffinity Technologies in the third quarter worth about $49,000. Finally, J. Safra Sarasin Holding AG bought a new stake in bioAffinity Technologies during the 1st quarter valued at $164,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.